Cell labelling for in vivo use and in process quality control
Lead Participant:
ALTRIKA LIMITED
Abstract
The consortium of Altrika, the University of Edinburgh’s School of Chemistry, Roslin Cellab and Barts and The London bring R&D, manufacturing, clinical and commercialisation experience to the challenge of tracking clinically relevant cell populations in vitro and in vivo. The absence of an in vivo tracking methodology leads to R&D, manufacturing and clinical constraints, valuable researcher time and cell yield losses, and associated costs. This project utilises an innovative, non-toxic cell label that is stable, cost-effective and easy to detect. It will demonstrate applicability to a range of regenerative medicine therapies for unmet clinical needs, as well as increasing the efficiency of R&D activities and manufacturing processes, and improving the efficacy of clinical delivery. Given the growth of regenerative medicine, this platform could reduce industry costs by as much as $275m in 2020.
Lead Participant | Project Cost | Grant Offer |
---|---|---|
ALTRIKA LIMITED | £310,414 | £ 186,248 |
  | ||
Participant |
||
QUEEN MARY UNIVERSITY OF LONDON | ||
ROSLIN CELLAB | £87,393 | £ 52,436 |
QUEEN MARY UNIVERSITY OF LONDON | £162,282 | |
UNIVERSITY OF EDINBURGH | £51,108 |
People |
ORCID iD |